new risk management programs with Abstral (AB-stral) and other immediate-release fentanyl products

You'll see new risk management programs with Abstral (AB-stral) and other immediate-release fentanyl products.

Abstral is a new sublingual tab that will compete with the lozenge (Actiq, etc)...buccal tab (Fentora, etc)...and buccal film (Onsolis).

These are ONLY for breakthrough pain in cancer patients who are already on chronic opioids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote